ID   SEMK2-M1
AC   CVCL_S907
DR   cancercelllines; CVCL_S907
DR   Wikidata; Q54952798
RX   PubMed=12620411;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80342; B acute lymphoblastic leukemia with t(v;11q23.3) MLL rearranged
DI   ORDO; Orphanet_585918; B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S906 ! SEMK2
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=12620411; DOI=10.1016/S1535-6108(03)00003-5;
RA   Armstrong S.A., Kung A.L.-J., Mabon M.E., Silverman L.B., Stam R.W.,
RA   Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A.,
RA   Golub T.R., Griffin J.D., Korsmeyer S.J.;
RT   "Inhibition of FLT3 in MLL. Validation of a therapeutic target
RT   identified by gene expression based classification.";
RL   Cancer Cell 3:173-183(2003).
//